Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Solid cancer is a leading global cause of mortality with limited therapeutic options.
• Plant-derived triterpenoids possess diverse pharmacological properties, including anticancer effects.
• Synthetic derivatives like CDDO-Me have been developed to enhance antitumor activity.

Purpose of the Study:

• To critically review preclinical evidence on the cancer-preventive and therapeutic activity of CDDO-Me.
• To present in vitro and in vivo effects of CDDO-Me.
• To elucidate the molecular mechanisms underlying CDDO-Me's anticancer actions.

Main Methods:

• Literature review of preclinical studies.
• Analysis of in vitro assays assessing cytotoxicity against cancer cells.
• Evaluation of in vivo studies in animal models for efficacy and safety.

Main Results:

• CDDO-Me exhibits significant cytotoxicity against various cancer cell lines.
• Preclinical animal models demonstrate cancer-preventive and therapeutic efficacy of CDDO-Me.
• Specific molecular pathways targeted by CDDO-Me are identified.

Conclusions:

• CDDO-Me represents a promising synthetic triterpenoid derivative for solid cancer treatment.
• Further research into its mechanisms and clinical potential is warranted.
• CDDO-Me could offer a novel therapeutic strategy for solid cancers.